Hepalink filed their IPO document with the HK stock exchange.  Much of what they write about RVX is well known to us.  Hepalink says they own 38.8% of RVX; I was under the impression that they were north of 40%.

https://www1.hkexnews.hk/app/sehk/2020/101221/documents/sehk20012300146.pdf

Page 307 of this document has the patents that have been filed by Hepalink for "RVX208".  Can someone please tell us if this is known stuff, or whether there is new patents being filed?  

On page 269, there is a blurb on Clinical Development Plan: 

Resverlogix has been continuously discussing with the FDA regarding the clinical development

approach based on phase III trial results. Resverlogix will include 11% of participants from

BETonMACE in the study of CKD indication and plans to move to phase III in 2020.

This is the first time I am hearing about moving to Phase 3 in 2020.  This could be the final trigger for a buyout, if the FDA approves our Breakthrough Therapy application.  It will confirm my belief that we have a kidney disease drug.